Zimmer Biomet: Solid Sales And Cash Flow Drive A Buy
Summary Zimmer Biomet had a strong third quarter, driven by robust sales and strong cash flow. Strong growth in the Hips, technology, and robotics segments offset the weak knee sales in Q3. My DCF valuation says the stock should be priced at around $124 per share. Given the current price…